BIOMx
Ness Ziona
About BIOMx
BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators: Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $146.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2025)
- Ticker: nysemkt:PHGE
- Website: biomx.com
- Phone: +1-844-972-0500
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/biomx-76236 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.